Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Florence

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Acta Clinica Belgica|May 30, 2024
A characterization of the HIV population with limited/exhausted treatment options: a multicenter Belgian studyRakan Nasreddine, Gilles Darcis, Jean Cyr Yombi, et al.
Trials|June 19, 2019
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapyWesley de Jong, Joeri Aerts, Sabine Allard, et al.
HIV Medicine|April 10, 2023
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Eric Florence, Jean Cyr Yombi, et al.
Sexual Health|December 1, 2018
High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reportsBea Vuylsteke, Thijs Reyniers, Catherine Lucet, et al.
HIV Medicine|August 8, 2022
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Jean Cyr Yombi, Gilles Darcis, et al.
BMC Public Health|August 23, 2024
Pre-exposure prophylaxis (PrEP) use trajectories and incidence of HIV and other sexually transmitted infections among PrEP users in Belgium: a cohort analysis of insurance claims data from 2017 to 2019Anke Rotsaert, Tom Smekens, David Jaminé, et al.
Plos One|April 12, 2012
Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPTRafael Van den Bergh, Sébastien Morin, Hans Jürgen Sass, et al.
Journal of Travel Medicine|December 29, 2023
Failure of artemether-lumefantrine therapy in travellers returning to Belgium with Plasmodium falciparum malaria: an observational case series with genomic analysisJan Pierreux, Emmanuel Bottieau, Eric Florence, et al.
Open Forum Infectious Diseases|May 9, 2017
Clinical Utility of the Nonstructural 1 Antigen Rapid Diagnostic Test in the Management of Dengue in Returning Travelers With FeverRalph Huits, Patrick Soentjens, Ula Maniewski-Kelner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Acta Clinica Belgica|May 30, 2024
A characterization of the HIV population with limited/exhausted treatment options: a multicenter Belgian studyRakan Nasreddine, Gilles Darcis, Jean Cyr Yombi, et al.
Trials|June 19, 2019
iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapyWesley de Jong, Joeri Aerts, Sabine Allard, et al.
HIV Medicine|April 10, 2023
Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Eric Florence, Jean Cyr Yombi, et al.
Sexual Health|December 1, 2018
High uptake of pre-exposure prophylaxis (PrEP) during early roll-out in Belgium: results from surveillance reportsBea Vuylsteke, Thijs Reyniers, Catherine Lucet, et al.
HIV Medicine|August 8, 2022
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in BelgiumRakan Nasreddine, Jean Cyr Yombi, Gilles Darcis, et al.
BMC Public Health|August 23, 2024
Pre-exposure prophylaxis (PrEP) use trajectories and incidence of HIV and other sexually transmitted infections among PrEP users in Belgium: a cohort analysis of insurance claims data from 2017 to 2019Anke Rotsaert, Tom Smekens, David Jaminé, et al.
Plos One|April 12, 2012
Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPTRafael Van den Bergh, Sébastien Morin, Hans Jürgen Sass, et al.
Journal of Travel Medicine|December 29, 2023
Failure of artemether-lumefantrine therapy in travellers returning to Belgium with Plasmodium falciparum malaria: an observational case series with genomic analysisJan Pierreux, Emmanuel Bottieau, Eric Florence, et al.
Open Forum Infectious Diseases|May 9, 2017
Clinical Utility of the Nonstructural 1 Antigen Rapid Diagnostic Test in the Management of Dengue in Returning Travelers With FeverRalph Huits, Patrick Soentjens, Ula Maniewski-Kelner, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2015
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical TrialSharon Walmsley, Axel Baumgarten, Juan Berenguer, et al.
Pageof 12